NEA and SR One led a $80m Series B round in CHARM Therapeutics.

NEA and SR One, a venture capital firms, led an $80m Series B round in CHARM Therapeutics, a biotechnology company, with participation from OrbiMed, F-Prime, Khosla Ventures and NVIDIA. “CHARM has leveraged its proprietary protein-ligand co-folding platform DragonFold to rapidly identify highly potent, next-generation menin inhibitors that are active against resistant mutations. We are excited to support progression of this program into clinical trials and look forward to working with the team," Mahesh Kudari, SR One Senior Associate.